Drug Price Trends for KETALAR

Average Pharmacy Cost for KETALAR

These are average pharmacy acquisition costs (net of discounts) from a US national survey

Drug Name	NDC	Price/Unit ($)	Unit	Date
KETALAR 500 MG/10 ML VIAL	42023-0114-10	0.66824	ML	2026-06-17

KETALAR market analysis, pricing projections, and patent/regulatory exclusivity outlook

Last updated: June 24, 2026

Executive summary

• Ketamine injection (brand name KETALAR) is an established, off-patent anesthesia and procedural analgesic with a mature generic supply chain in the US. Market value is dominated by low-cost multisource products rather than KETALAR-specific pricing power.
• Near-term pricing is primarily shaped by (1) FDA supply continuity for ketamine injection, (2) wholesaler contract pricing and tendering for hospital systems, and (3) competitive pricing from generics; KETALAR’s brand premium typically compresses as generics gain share.
• In the absence of verified, current KETALAR list price and payer-reimbursement specifics, pricing projections should be treated as ranges driven by generic reference pricing mechanics and ongoing procurement competition.

What is KETALAR (ketamine) and how is it used in hospitals?

KETALAR is ketamine hydrochloride for injection used for anesthesia induction and maintenance, procedural sedation, and other settings depending on labeling and clinical protocol. Commercial demand is tied to:

• Surgery volumes (inpatient and outpatient)
• Procedural sedation growth and ED/anesthesiology utilization patterns
• Hospital formulary decisions and group purchasing organization (GPO) contracting
• Supply stability of controlled substances and active ingredient sourcing

Where does KETALAR fit in perioperative care?

Ketamine is positioned as:

• An anesthetic agent for induction and maintenance in certain anesthesia plans
• A sedative/analgesic for procedural sedation when clinically appropriate
• A cost-sensitive option vs alternatives depending on formulary and pathway-specific protocols

Which dosage forms drive spend?

KETALAR is sold as injection; spend is typically concentrated in hospital-administered volumes and distributed through standard pharmaceutical channels, with procurement pricing heavily influenced by contracting.

How big is the US ketamine injection market and what portion is likely KETALAR?

A precise, product-specific share for KETALAR requires current IMS/IQVIA or equivalent product-channel data, plus verified KETALAR NDC-level shipment statistics. Without those inputs, a defensible approach is to treat the market as primarily generic-multisource with brand share determined by formulary preference and contracting.

Key demand drivers

• Outpatient surgery expansion increases procedural sedation exposure.
• ED sedation protocols in some systems increase ketamine’s “safety and efficacy” utilization, subject to local governance.
• Budget pressure pushes hospitals toward the lowest-cost compliant supplier under tender.

Key constraints

• Controlled substance handling and storage requirements can increase operational costs even when drug acquisition cost is low.
• Any supply disruptions tend to transiently raise acquisition costs for all ketamine products, including brands.

Why do KETALAR prices behave like a generic-dominated hospital commodity?

KETALAR is a legacy brand in a drug class with extensive generic competition. Brand pricing typically follows:

• Reference pricing and wholesale contract pricing practices
• Substitution at point of dispensing and hospital inventory switching
• Tender cycles and group purchasing contracts

What determines realized acquisition price?

• Net price after rebates and contract terms
• Hospital procurement timing and purchase-order mix
• Contracted competitor baskets (multiple-source tenders)

What determines list price behavior?

• List price can remain high while net pricing is compressed.
• In bulk purchasing, list-to-net ratios matter more than list price alone.

How strong is the patent estate for KETALAR and ketamine injection in the US?

KETALAR’s active ingredient is ketamine. Ketamine itself is long-established and is widely available as generics in the US market. For ketamine injection, the competitive landscape is typically dominated by:

• Generic drug products using bioequivalent ketamine hydrochloride
• Formulation or method-of-use patents only if they meet enforceable novelty standards

What patents usually matter in this category?

In older, generic-dominant products, the practical IP constraints on generics tend to shift from composition patents to:

• Specific formulation improvements (if enforceable and still active)
• Specific labeling or method-of-use indications (if enforceable)
• Exclusivities tied to specific FDA approvals (if any single NDA/BLA has a newer exclusivity trigger)

Litigation and exclusivity

Brand-specific Paragraph IV litigation and settlements occur when a brand has enforceable unexpired patents or exclusivities. For legacy ketamine injection brands like KETALAR, generic entry is typically already established unless a later-protected formulation or a newer NDA created a fresh exclusivity window.

What is the Orange Book status of KETALAR?

Orange Book status governs listed patents and exclusivity for specific approved NDA product entries. Determining the exact status for KETALAR requires NDC-level Orange Book lookup and current listings. Without those live listings, no definitive statement can be made about:

• Whether KETALAR has active listed patents today
• Which specific patent numbers are listed
• Whether any exclusivity periods still exist for a specific KETALAR NDA

When does ketamine injection lose exclusivity for KETALAR in the US?

Ketamine injection generics are already marketed widely; KETALAR’s exclusivity would, in the practical market, have already lapsed. Any remaining legal barriers would have to be tied to specific product-specific formulation patents or a still-active patent or exclusivity attached to a specific NDA/NDC.

What Paragraph IV challenges or generic entry risks exist for KETALAR?

For most legacy ketamine injection brands, Paragraph IV entry risk is low because:

• Multisource generics are already present
• Patent and exclusivity barriers, if any, would have already been tested in the market

A current risk assessment for KETALAR specifically requires:

• Orange Book patent list and expiry dates
• Whether any ANDA applicants have current FDA 180-day exclusivity triggers

How do KETALAR prices compare with generic ketamine injection?

In generic-dominated hospital markets:

• KETALAR’s realized price is typically higher than the contracted lowest-cost generic.
• Brand retention usually occurs when the brand is bundled in a contract basket or when switching is operationally costly (inventory protocols, standardized labeling, or clinician preference).

Competitive benchmarks that drive price compression

• 340B and institutional procurement dynamics for hospital acquisition
• PBM formulary dynamics for outpatient settings (ketamine use is more procedural than chronic, so exposure differs from typical PBM-driven chronic spend)

What are realistic KETALAR price projections (range-based) for the next 12 to 36 months?

Because ketamine injection is commodity-like in most healthcare systems and KETALAR is a legacy brand, near-term pricing trajectories typically show:

• Mild declines or flat net pricing for the brand relative to generic cost leadership
• Periodic spikes limited to supply disruptions, then reversion after supply normalizes

Projection framework (hospital procurement reality)

Use three scenarios:

Scenario 1: Normal supply, competitive tenders

• Net price: flat to slightly down (low single digits annually) versus generic reference trend
• Expected brand share: stable to slight decline

Scenario 2: Mild supply tightness

• Net price: short-term uptick while contracted supply is constrained
• Expected duration: weeks to a few months
• Brand relative pricing: can widen temporarily versus generics with stronger supply

Scenario 3: Supply disruption with broad market impact

• Net price: temporary increase across all ketamine products
• After stabilization: sharp reversion as new supply returns and tenders reset

What drives scenario probabilities?

• Active ingredient manufacturing continuity
• Regulatory enforcement actions affecting manufacturing lots
• Controlled substance supply chain shocks

Which companies supply ketamine injection and how does that affect KETALAR pricing?

KETALAR is generally priced against a dense field of generics, so market behavior is driven by the lowest-cost bidders in hospital tenders. The practical impact:

• If generic competitors add capacity, KETALAR price leverage drops.
• If competitors face supply constraints, KETALAR can gain relative pricing temporarily through availability.

How do FDA regulatory pathways and labeling changes affect pricing for KETALAR?

For a mature injectables market, FDA pathway effects are mostly indirect:

• New ANDAs typically compete on bioequivalence and labeling alignment.
• Labeling revisions that change sedation/anesthesia guidance can alter tender dynamics if hospitals adopt protocol-specific drug choice criteria.

What regulatory events matter most

• Changes in boxed warnings, contraindications, or controlled substance restrictions
• Risk evaluation or distribution constraints that affect availability

What commercial risks and upside could change KETALAR pricing?

Commercial upside scenarios for a legacy brand are usually tied to:

• Supply gaps where brand availability is superior to certain generics
• Contract awards that require brand usage for a period
• Short-lived shortages due to manufacturing disruptions

Commercial risks:

• Ongoing substitution by hospital formularies to lower-cost ketamine generics
• PBM or institutional contracting changes that disfavor legacy brands
• Regulatory findings that force lot recalls and disrupt brand distribution

What does the competitive landscape look like versus other anesthetics?

Ketamine’s key comparators include:

• Propofol for procedural sedation and anesthesia induction
• Etomidate (where used), midazolam-based regimens, and other sedative/analgesic combinations

Price matters when:

• Hospitals blend ketamine into sedation pathways where cost per case is tracked
• Staff prefer a standard protocol based on availability and turnaround time

Key takeaways

• KETALAR’s market and pricing are shaped primarily by generic competition and hospital procurement contracting rather than brand-specific exclusivity.
• Base-case pricing behavior is flat to slightly down in net terms under normal supply and continued tender competition.
• Meaningful price increases are most plausible only during supply tightness or broad market disruptions, followed by reversion once supply stabilizes.
• Patent and exclusivity leverage for KETALAR, if any, would need to be confirmed via Orange Book NDC listings and active patent expiry schedules; the practical market outcome for ketamine injection is dominated by multisource generics.

FAQs

1. What factors most influence realized net pricing for ketamine injection in US hospitals?
   Contract terms, tender timing, and the availability of the lowest-cost multisource supplier.

2. Do supply disruptions for ketamine injection typically raise prices for both brands and generics?
   Yes. Short-term price increases usually apply across ketamine products, with relative effects depending on each manufacturer’s ability to deliver.

3. How does hospital formulary switching affect KETALAR demand?
   Switching reduces brand pull-through by shifting procurement to the contracted lowest-cost generic basket.

4. Are Paragraph IV challenges still relevant for KETALAR specifically?
   They are generally lower relevance for long-established ketamine injection brands where multisource generics are already present.

5. What FDA-related events could impact ketamine injection pricing?
   Lot recalls, manufacturing disruptions, labeling changes that drive protocol selection, and distribution constraints.

References

(No sources cited because no verified, current Orange Book listings, FDA approval/NDC data, or market pricing datasets were provided in the prompt.)